Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 990 across all filing types
Latest filing 2026-03-26 Remuneration Information
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
董事会薪酬与考核委员会关于公司2026年员工持股计划相关事项的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding the company's 2026 Employee Stock Ownership Plan (ESOP). It references compliance with relevant laws and regulations, confirms the legality and appropriateness of the ESOP, and supports its submission to the Board for approval. The content focuses on remuneration-related governance and employee incentive plans rather than financial results, audit, or general corporate governance structure. The document length is short (1526 characters) and it is a committee opinion on a remuneration-related matter. Therefore, it fits best under Remuneration Information filings, which cover compensation and employee incentive plans.
2026-03-26 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司使用部分闲置募集资金及自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (长城证券股份有限公司) regarding the use of idle raised funds and own funds by 浙江泰林生物技术股份有限公司 for cash management. It includes information about the raised funds, investment purpose, investment amount, investment methods, risk analysis, and the sponsor's verification opinion. The document references regulatory compliance and approvals but does not contain financial statements or quarterly/yearly financial results. It is a regulatory compliance and verification report related to fundraising and fund usage, not a full annual or interim report, earnings release, or capital update. The document length is under 5,000 characters and is a formal verification opinion, which fits best under Regulatory Filings (RNS) as it does not constitute a full financial report or announcement of a report publication.
2026-03-26 Chinese
前次募集资金使用情况报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by Zhejiang Tailin Biotechnology Co., Ltd., including amounts raised, usage, changes in investment projects, idle fund management, and investment project benefits. It references regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes financial figures and project status up to December 31, 2025. The content focuses on the use of proceeds from a convertible bond issuance, project investment details, and compliance with regulatory requirements for fund usage reporting. This matches the characteristics of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital usage. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP.
2026-03-26 Chinese
关于向不特定对象发行可转换公司债券摊薄即期回报、采取填补措施及相关承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by Zhejiang Tailin Biotechnology Co., Ltd. regarding the issuance of convertible bonds to unspecified investors. It discusses the dilution impact on immediate returns, risk factors, necessity and rationality of the issuance, investment projects, and measures to compensate for dilution of immediate returns. It includes detailed financial assumptions, projections, and commitments by the company's board and senior management to ensure the fulfillment of these measures. The document references regulatory guidelines and compliance with Chinese securities regulations. It is not a full financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a detailed capital/financing update related to a convertible bond issuance and its financial impact, including mitigation measures and commitments. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-26 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled as a remuneration management system for directors and senior management of Zhejiang Tailin Biotechnology Co., Ltd. It details the principles, standards, payment, and clawback policies related to compensation for directors and senior executives. There is no financial data, audit information, or report publication mentioned. The content is focused on compensation policies and governance related to remuneration. This matches the definition of a Remuneration Information filing, which reports compensation details for top executives and directors.
2026-03-26 Chinese
审计委员会对2025年度会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Audit Committee of Zhejiang Tailin Biotechnology Co., Ltd. regarding the supervision of the accounting firm Tianjian for the fiscal year 2025. It details the audit firm's qualifications, the process of reappointment, the committee's oversight activities, and an overall evaluation of the audit firm's performance. The document focuses on the audit committee's review and supervision of the external auditor's work rather than presenting the full audit report or financial statements. The length is 1966 characters, which is relatively short and consistent with a standalone audit-related report rather than a full annual report or audit report. This matches the description of an Audit Report / Information (AR) filing, which includes standalone audit reports and results of internal or regulatory stress tests, excluding full annual reports. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-03-26 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.